Hydrogel Embedded Dexamethasone for the Traumatic Brain Injury (TBI)
Awarded Limited / Sole Source Justification Posted
- Solicitation number
- W81XWH20C0114
- Agency
-
Medical Command
Department of the Army, Department of Defense
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- W81XWH20C0114 Federal contract award
- Awardee
- Clemson University
Notice details come from SAM.gov. Updated .
About this opportunity
This Limited/Sole Source Justification Notice from the Department of the Army Medical Command supports a sole source award to Clemson University for research and development services involving the delivery of hydrogel embedded dexamethasone to treat traumatic brain injury. The Walter Reed Army Institute of Research requires a contractor to determine the pharmacokinetic profile and therapeutic efficacy of dexamethasone-embedded hydrogel treatment on measures of brain injury, inflammation, and cognitive and motor function outcomes over a three year period from 2020 to 2023. Due to Clemson University's patented intellectual property rights related to the hydrogel, no other sources were considered capable of meeting this requirement, resulting in an estimated total award value of $X to the university.
Notice text
Awarded contract W81XWH20C0114 to unknown vendor for unknown amount on 2020-08-31.
Files
| File | Type | Posted |
|---|---|---|
| A02-1-Redacted-Amended-JA-Hydrogel-2_Redacted.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| This notice | Limited / Sole Source Justification | |
| Hydrogel Embedded Dexamethasone for the Traumatic Brain Injury (TBI) | Special Notice |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity